European Journal of Cancer
Volume 44, Issue 8 , Pages 1105-1115 , May 2008

Management of malignant bowel obstruction

  • Carla Ida Ripamonti

      Affiliations

    • Professor on Contract of Oncology (Teaching Palliative Medicine) at the School of Specialization in Oncology, University of Milan
    • Palliative Care Unit (Pain Therapy-Rehabilitation) IRCCS Foundation, National Cancer Institute, Milano Italy
    • Corresponding Author InformationCorresponding author: Address. Palliative Care Unit (Pain Therapy-Rehabilitation) IRCCS Foundation, National Cancer Institute, Milano Italy. Tel.: +39 02 23902243; fax. +39 02 23903656.
    • ,
  • Alexandra M. Easson

      Affiliations

    • Assistant Professor of Surgery, University of Toronto, Division of General Surgery, Mount Sinai Hospital, Department of Surgical Oncology, Princess Margaret Hospital Toronto, Ontario Canada
    • ,
  • Hans Gerdes

      Affiliations

    • Attending Physician, Director of GI Endoscopy, Memorial Sloan-Kettering Cancer Center, and Professor of Clinical Medicine, Weill Medical College of Cornell University

Received 11 February 2008 ,Accepted 25 February 2008.

References 

  1. Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage. 2007;34:S49–S59
  2. Ripamonti C, Bruera E. Palliative management of malignant bowel obstruction. Int J Gynecol Cancer. 2002;12:135–143
  3. Krouse RS. The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research. J Pain Symptom Manage. 2007;34:S1–S6
  4. Legendre H, Vanhuyse F, Caroli-Bosc FX, et al. Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. Eur J Surg Oncol. 2001;27:364–367
  5. Suri S, Gupta S, Sudhakar PJ, et al. Comparative evaluation of plain films, ultrasound and CT in the diagnosis of intestinal obstruction. Acta Radiol. 1999;40:422–428
  6. Thompson WM, Kilani RK, Smith BB, et al. Accuracy of abdominal radiography in acute small-bowel obstruction: does reviewer experience matter?. AJR Am J Roentgenol. 2007;188:W233–W238
  7. De Bree E, Koops W, Kroger R, et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86:64–73
  8. Jacquet P, Jelinek JS, Steves MA, et al. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72:1631–1636
  9. Taourel PG, Fabre JM, Pradel JA, et al. Value of CT in the diagnosis and management of patients with suspected acute small-bowel obstruction. AJR Am J Roentgenol. 1995;165:1187–1192
  10. Beall DP, Fortman BJ, Lawler BC, et al. Imaging bowel obstruction: a comparison between fast magnetic resonance imaging and helical computed tomography. Clin Radiol. 2002;57:719–724
  11. Easson AM, Lee KF, Brasel K, et al. Clinical research for surgeons in palliative care: challenges and opportunities. J Am Coll Surg. 2003;196:141–151
  12. McCahill LE, Krouse RS, Chu DZ, et al. Decision making in palliative surgery. J Am Coll Surg. 2002;195:411–422
  13. Bryan D, Radbod R, Berek J. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer. 2004;16:125–134
  14. Higashi H, Shida H, Ban K, et al. Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer. Jpn J Clin Oncol. 2003;33:357–359
  15. Spiegel D. Effects of psychotherapy on cancer survival. Nat Rev Cancer. 2002;2:383–389
  16. Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001;9:223–233
  17. Helyer LK, Law CH, Butler M, et al. Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol. 2007;14:1264–1271
  18. Abbas SM, Merrie AE. Resection of peritoneal metastases causing malignant small bowel obstruction. World J Surg Oncol. 2007;5:122
  19. Hofmann B, Heheim LL, Soreide JA. Ethics of palliative surgery in patients with cancer. Br J Surg. 2005;92:809
  20. Tattersall MH, Butow PN, Clayton JM. Insights from cancer patient communication research. Hematology Oncology Clinics of North America. 2002;16:731–743
  21. Hofmann B, Haheim LL, Soreide JA. Ethics of palliative surgery in patients with cancer. Br J Surg. 2005;92:802–809
  22. Tattersall MH, Butow PN, Clayton JM. Insights from cancer patient communication research. Hematol Oncol Clin North Am. 2002;16:731–743
  23. Lowe AS, Beckett CG, Jowett S, et al. Self-expandable metal stent placement for the palliation of malignant gastroduodenal obstruction: experience in a large, single, UK centre. Clin Radiol. 2007;62:738–744
  24. Telford JJ, Carr-Locke DL, Baron TH, et al. Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study. Gastrointest Endosc. 2004;60:916–920
  25. Dormann A, Meisner S, Verin N, et al. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy. 2004;36:543–550
  26. Nassif T, Prat F, Meduri B, et al. Endoscopic palliation of malignant gastric outlet obstruction using self-expandable metallic stents: results of a multicenter study. Endoscopy. 2003;35:483–489
  27. Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice?. Gastrointest Endosc. 2004;60:1010–1017
  28. Espinel J, Sanz O, Vivas S, et al. Malignant gastrointestinal obstruction: endoscopic stenting versus surgical palliation. Surg Endosc. 2006;20:1083–1087
  29. Lillemoe KD, Cameron JL, Hardacre JM, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999;230:322–328discussion 328-30
  30. Jeurnink SM, Steyerberg EW, Hof GV, et al. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients. J Surg Oncol. 2007;
  31. Wong YT, Brams DM, Munson L, et al. Gastric outlet obstruction secondary to pancreatic cancer: surgical vs endoscopic palliation. Surg Endosc. 2002;16:310–312
  32. Mehta S, Hindmarsh A, Cheong E, et al. Prospective randomized trial of laparoscopic gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction. Surg Endosc. 2006;20:239–242
  33. Schmidt C, Gerdes H, Hawkins W, et al. Palliation for malignant gastric outlet obstruction: A prospective quality of life study. Manuscript in Preparation.
  34. Camunez F, Echenagusia A, Simo G, et al. Malignant colorectal obstruction treated by means of self-expanding metallic stents: Effectiveness before surgery and in palliation. Radiology. 2000;216:492–497
  35. Law WL, Chu KW, Ho JW, et al. Self-expanding metallic stent in the treatment of colonic obstruction caused by advanced malignancies. Dis Colon Rectum. 2000;43:1522–1527
  36. Mainar A, De Gregorio MA, Tejero E, et al. Acute colorectal obstruction: Treatment with self-expandable metallic stents before scheduled surgery—Results of a multicenter study. Radiology. 1999;210:65–69
  37. Nash CL, Markowitz AJ, Schattner M, et al. Colorectal stents for the management of malignant large bowel obstruction. Gastrointest Endo. 2002;55:AB216
  38. Pothuri B, Guiguis A, Gerdes H, et al. The use of colorectal stents for palliation of large bowel obstruction due to recurrent gynecologic cancer. Gynecol Oncol. 2004;95:513–517
  39. Khot UP, Wenk Lang A, Murali K, et al. Systematic review of the efficacy and safety of colorectal stents. Br J Surg. 2002;89:1096–1102
  40. Sebastian S, Johnston S, Geoghegan T, et al. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastro. 2004;99:2051–2057
  41. Campagnutta E, Cannizzaro R, Gallo A, Zarrelli A, Valentini M, De Cicco M, et al. Palliative Treatment of Upper Intestinal Obstruction by Gynecological Malignancy: The Usefulness of Percutaneous Endoscopic Gastrostomy. Gynecologic Oncology. 1996;62:103–105
  42. Pothuri B, Montemarano M, Gerardi M, Shike M, Ben-Porat L, Sabbatinin P, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecologic Oncology. 2005;96:330–334
  43. World Health Organization . Cancer Pain Relief. second ed.. Geneve: WHO; 1996;
  44. Mercadante S. What is the opioid of choice? Progress Palliat Care, in press.
  45. Mercadante S, Sapio M, Serretta R. Treatment of pain in chronic bowel subobstruction with self-administration of methadone. Support Care Cancer. 1997;5:327–329
  46. Hanks GW, De Conno F, Cherny N, et al. Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer. 2001;84/5:587–593
  47. Anderson SL, Shreve ST. Continuous subcutaneous infusion of opiates at the end-life. Ann Pharmacother. 2004;38:1015–1023
  48. Ripamonti C, Bruera E. Current status of patient-controlled analgesia in cancer patients. Oncology. 1997;11:373–384
  49. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokin. 2000;38:59–89
  50. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl. An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001;61:2289–2307
  51. Böhme K. Buprenorphine in a transdermal therapeutic system – a new option. Clin Rheumatol. 2002;Suppl 1:S13–S16
  52. Fainsinger RL, Spachynski K, Hanson J, et al. Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage. 1994;9:12–18
  53. Ventafridda V, Ripamonti C, Caraceni A, et al. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumouri. 1990;76:389–393
  54. Mercadante S. Pain in inoperable bowel obstruction. Pain Digest. 1995;5:9–13
  55. De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Sympt Manage. 1991;6:484–486
  56. Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction having a nasogastric tube. A prospective, randomized clinical trial. J Pain Symptom Manage. 2000;19:23–34
  57. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Supportive Care in Cancer. 2000;8:188–191
  58. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study. Lancet. 1985;2:990–993
  59. Isbister WH, Elder P, Symons L. Non-operative management of malignant intestinal obstruction. J R Coll Surg Edinb. 1990;35:369–372
  60. Mercadante S, Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage. 1992;7(8):496–498
  61. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliative Medicine. 1993;7:295–299
  62. Khoo D, Riley J, Waxman J. Control of emesis in bowel obstruction in terminally ill patients. The Lancet. 1992;339:375–376
  63. Riley J, Fallon MT. Octreotide in terminal malignant obstruction of the gastrointestinal tract. European J Palliative Care. 1994;1/1:20–22
  64. Stiefel F, Morant R. Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Supportive Care Cancer. 1993;1:57–58
  65. Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecologic Oncology. 1996;61:345–348
  66. Davis MP, Furste A. Glycopyrrolate: a useful drug in the Palliation of Mechanical Bowel Obstruction. J Pain Symptom Manage. 1999;18:153–154
  67. Ripamonti C, Panzeri C, Groff L, Galeazzi G, Boffi R. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results. Tumouri. 2001;87:1–9
  68. Anthone GJ, Bastidas JA, Orlandle MS, Yeo CJ. Direct proabsorptive effect of octreotide on ionic transport in the small intestine. Surgery. 1990;108:1136–1142
  69. Basson MD, Fielding LP, Bilchik AJ, et al. Does vasoactive intestinal polypeptide mediate the pathophysiology of bowel obstruction?. Am J Surg. 1989;157:109–115
  70. Neville R, Fielding P, Cambria RP, Modlin I. Vascular responsiveness in obstructed gut. Dis Colon Rectum. 1991;34:229–235
  71. Nellgard P, Bojo L, Cassuto J. Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction. Scand J Gastroenterol. 1995;30:464–469
  72. Mercadante S, Kargar J, Nicolosi G. Octreotide may prevent definitive intestinal obstruction. J Pain Symptom Manage. 1997;13:352–355
  73. Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage. 2004;28:412–416
  74. Steadman K, Franks A. A woman with malignant bowel obstruction who did not want to die with tubes. Lancet. 1996;347:944
  75. Mercadante S, Avola G, Maddaloni S, et al. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients. Support Care Cancer. 1996;4:393–394
  76. Sun X, Li X, Li H. Management of intestinal obstruction in advanced ovarian cancer: an analysis of 57 cases [in Chinese]. Zhonghua Zhong Liu Za Zhi. 1995;17:39–42
  77. Twycross R, Back I, et al. Nausea and vomiting in advanced cancer. European J of Palliative Care. 1998;5(2):39–45
  78. Feuer DJ, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol. 1999;10:1035–1041
  79. Cozzaglio L, et al. Outcome of cancer patients receiving home parenteral nutrition. J Parenteral Enteral Nutrition. 1997;21:339–342
  80. Hoda D, Jatoi A, Burnes J, Loprinzi C, Kelly D. Should patients with advanced, incurable cancers ever be sent home with Total parenteral nutrition?. Cancer. 2005;103:863–868
  81. Burge FI. Dehydration symptoms of palliative care cancer patients. J Pain Symptom Manage. 1993;8:454–464
  82. Fainsinger RL, MacEachern T, Miller MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Sympt Manage. 1994;9:298–302
  83. Ventafridda et al. (2003) Mouth care. In: Doyle D, Hanks GWC, Cherny N, et al., editors. Oxford Textbook of palliative medicine, 3rd ed. Oxford: Oxford University Press; 2005.

PII: S0959-8049(08)00139-1

doi: 10.1016/j.ejca.2008.02.028

European Journal of Cancer
Volume 44, Issue 8 , Pages 1105-1115 , May 2008

Article Tools

* Image Usage & Resolution